Levocabastine, a selective H1-receptor antagonist, has been evaluated in the management of allergic conjunctivitis and its efficacy was compared between the skin test positive and negative groups. A total of 20 patients who was clinically diagnosed as allergic conjunctivitis were processed for the skin test. According to the results of skin test, patients were divided into two groups; skin test positive (15) and negative (5). Livostin(levocabastine 0.5mg/ml) eye drops were topically instilled 2 times per day for 1 week. Both subjective and objective findings were assessed by a 4-point scase (0=none, 1=mild, 2=moderate, 3=severe). The parameters used for the examination of drug effectiveness were itching, tearing, chemosis, lid swelling and injection. 85.5% (17 put of 20) of the patients showed effects on the management of their symptoms and signs. No significant difference was observed in its effectiveness between skin test positive and negative groups. The results of present clinical trials suggest that Livostin eye drops may be an attractive therapeutic option for the management of allergic conjunctivitis.